Literature DB >> 17881663

Bosentan therapy for patients with severe Raynaud's phenomenon in systemic sclerosis.

M E Hettema, D Zhang, H Bootsma, C G M Kallenberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17881663      PMCID： PMC1994313          DOI： 10.1136/ard.2007.073684

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  10 in total

Review 1.  Endothelin and endothelin receptor antagonists in systemic rheumatic disease.

Authors:  Maureen D Mayes
Journal:  Arthritis Rheum       Date:  2003-05

2.  Once daily felodipine in patients with primary Raynaud's phenomenon.

Authors:  C G Kallenberg; A A Wouda; L Meems; H Wesseling
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.

Authors:  F M Wigley; J H Korn; M E Csuka; T A Medsger; N F Rothfield; M Ellman; R Martin; D H Collier; A Weinstein; D E Furst; S A Jimenez; M D Mayes; P A Merkel; B Gruber; L Kaufman; J Varga; P Bell; J Kern; P Marrott; B White; R W Simms; A C Phillips; J R Seibold
Journal:  Arthritis Rheum       Date:  1998-04

4.  Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.

Authors:  J H Korn; M Mayes; M Matucci Cerinic; M Rainisio; J Pope; E Hachulla; E Rich; P Carpentier; J Molitor; J R Seibold; V Hsu; L Guillevin; S Chatterjee; H H Peter; J Coppock; A Herrick; P A Merkel; R Simms; C P Denton; D Furst; N Nguyen; M Gaitonde; Carol Black
Journal:  Arthritis Rheum       Date:  2004-12

5.  Reproducibility of the finger cooling test.

Authors:  M L Bartelink; H Wollersheim; R W Jansen; A Theeuwes; T Thien
Journal:  Microvasc Res       Date:  1993-01       Impact factor: 3.514

6.  Nailfold capillaroscopy and laser Doppler fluxmetry for evaluation of Raynaud's phenomenon: how valid is the local cooling test?

Authors:  A Creutzig; S Hiller; R Appiah; J Thum; L Caspary
Journal:  Vasa       Date:  1997-08       Impact factor: 1.961

7.  Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study.

Authors:  F M Wigley; R A Wise; J R Seibold; D A McCloskey; G Kujala; T A Medsger; V D Steen; J Varga; S Jimenez; M Mayes; P J Clements; S R Weiner; J Porter; M Ellman; C Wise; L D Kaufman; J Williams; W Dole
Journal:  Ann Intern Med       Date:  1994-02-01       Impact factor: 25.391

8.  Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.

Authors:  F M Wigley; J R Seibold; R A Wise; D A McCloskey; W P Dole
Journal:  J Rheumatol       Date:  1992-09       Impact factor: 4.666

9.  Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study.

Authors:  C M Black; L Halkier-Sørensen; J J Belch; S Ullman; R Madhok; A J Smit; J D Banga; H R Watson
Journal:  Br J Rheumatol       Date:  1998-09

10.  Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.

Authors:  Peter A Merkel; Karen Herlyn; Richard W Martin; Jennifer J Anderson; Maureen D Mayes; Patrice Bell; Joseph H Korn; Robert W Simms; Mary Ellen Csuka; Thomas A Medsger; Naomi F Rothfield; Michael H Ellman; David H Collier; Arthur Weinstein; Daniel E Furst; Sergio A Jiménez; Barbara White; James R Seibold; Fredrick M Wigley
Journal:  Arthritis Rheum       Date:  2002-09
  10 in total
  10 in total

Review 1.  Targeted therapy for systemic sclerosis: how close are we?

Authors:  Manuel Ramos-Casals; Vicent Fonollosa-Pla; Pilar Brito-Zerón; Antoni Sisó-Almirall
Journal:  Nat Rev Rheumatol       Date:  2010-04-13       Impact factor: 20.543

2.  Digital ulcers in scleroderma patients: A retrospective observational study.

Authors:  A De Cata; M Inglese; F Molinaro; S De Cosmo; R Rubino; M Bernal; G Mazzoccoli
Journal:  Int J Immunopathol Pharmacol       Date:  2015-12-18       Impact factor: 3.219

Review 3.  Advances in the treatment of Raynaud's phenomenon.

Authors:  Terri L Levien
Journal:  Vasc Health Risk Manag       Date:  2010-03-24

4.  Expression of the oxygen-sensitive transcription factor subunit HIF-1α in patients suffering from secondary Raynaud syndrome.

Authors:  Lukas Andreas Heger; Mark Kerber; Marcus Hortmann; Samuel Robinson; Maximilian Mauler; Daniela Stallmann; Daniel Duerschmied; Christoph Bode; Christoph Hehrlein; Ingo Ahrens
Journal:  Acta Pharmacol Sin       Date:  2018-07-10       Impact factor: 6.150

5.  The safety of iloprost in systemic sclerosis in a real-life experience.

Authors:  S Bellando-Randone; C Bruni; G Lepri; G Fiori; F Bartoli; M L Conforti; A Moggi-Pignone; S Guiducci; D Giuggioli; M Colaci; A Spinella; C Ferri; M Matucci-Cerinic
Journal:  Clin Rheumatol       Date:  2018-02-22       Impact factor: 2.980

6.  Severe digital necrosis in a 4-year-old boy: primary Raynaud's or jellyfish sting.

Authors:  Fatih Koksal Binnetoglu; Betul Kizildag; Naci Topaloglu; Ozgur Kasapcopur
Journal:  BMJ Case Rep       Date:  2013-11-18

7.  Pharmacotherapy Options in the Management of Raynaud's Phenomenon.

Authors:  Alicia M Hinze; Fredrick M Wigley
Journal:  Curr Treatm Opt Rheumatol       Date:  2018-07-04

8.  Iontophoresis of endothelin receptor antagonists in rats and men.

Authors:  Matthieu Roustit; Sophie Blaise; Claire Arnaud; Marcin Hellmann; Claire Millet; Diane Godin-Ribuot; Boris Dufournet; Jean Boutonnat; Christophe Ribuot; Jean-Luc Cracowski
Journal:  PLoS One       Date:  2012-07-13       Impact factor: 3.240

9.  Endothelin Receptors Expressed by Immune Cells Are Involved in Modulation of Inflammation and in Fibrosis: Relevance to the Pathogenesis of Systemic Sclerosis.

Authors:  Tinazzi Elisa; Puccetti Antonio; Patuzzo Giuseppe; Barbieri Alessandro; Argentino Giuseppe; Confente Federico; Dolcino Marzia; Beri Ruggero; Marchi Giacomo; Ottria Andrea; Righetti Daniela; Rampudda Mariaelisa; Lunardi Claudio
Journal:  J Immunol Res       Date:  2015-05-18       Impact factor: 4.818

10.  No effects of bosentan on microvasculature in patients with limited cutaneous systemic sclerosis.

Authors:  Martha E Hettema; Dan Zhang; Ymkje Stienstra; Andries J Smit; Hendrika Bootsma; Cees G M Kallenberg
Journal:  Clin Rheumatol       Date:  2009-04-07       Impact factor: 2.980
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.